France has included health economic assessment (HEA) as an official criterion for innovative drug pricing since 2013. Until now, no cost-effectiveness threshold (CET) has been officially proposed to qualify incremental cost-effectiveness ratios (ICERs). Although the French health authorities have publicly expressed the need for such reference values, previous initiatives to determine these have failed. The study aims to propose a locally adapted method for estimating a preference-based value for a quality-adjusted life-year (QALY) based on a rational approach to public policy choices in France. Link to the article
PUYOU DE POUVOURVILLE, G., TÉHARD, B., DETOURNAY, B., BORGET, I. and ROZE, S. (2020). The Value of a QLY for France: a newapproach topropose acceptable reference values. Value in Health, 23(8), pp. 985-993.